Jump to content

Interferon alfa-2b: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
Filled in 1 bare reference(s) with reFill 2
cas
 
(37 intermediate revisions by 24 users not shown)
Line 22: Line 22:
| elimination_half-life =
| elimination_half-life =
<!-- Identifiers -->
<!-- Identifiers -->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number_Ref = {{cascite|changed|DrugBank}}
| CAS_number =
| CAS_number = 98530-12-2
| ATC_prefix = L03
| ATC_prefix = L03
| ATC_suffix = AB05
| ATC_suffix = AB05
Line 29: Line 29:
| PubChem =
| PubChem =
| IUPHAR_ligand = 8338
| IUPHAR_ligand = 8338
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00105
| DrugBank = DB00105
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL_Ref = {{ebicite|changed|EBI}}
Line 35: Line 35:
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| ChemSpiderID = none
| UNII = 43K1W2T1M6
<!-- Chemical data -->
<!-- Chemical data -->
| chemical_formula =
| chemical_formula =
| molecular_weight =
| molecular_weight =
}}
}}
'''Interferon alfa-2b''' is an antiviral or [[antineoplastic]] drug. It is a [[recombinant DNA|recombinant]] form of the protein [[IFNA2|Interferon alpha-2]] that was originally sequenced and produced recombinantly in ''[[E. coli]]''<ref>{{Cite journal|last=Nagata|first=Shigekazu|last2=Taira|first2=Hideharu|last3=Hall|first3=Alan|last4=Johnsrud|first4=Lorraine|last5=Streuli|first5=Michel|last6=Ecsödi|first6=Josef|last7=Boll|first7=Werner|last8=Cantell|first8=Kari|last9=Weissmann|first9=Charles|date=1980|title=Synthesis in E. coli of a polypeptide with human leukocyte interferon activity|url=https://www.nature.com/articles/284316a0|journal=Nature|language=en|volume=284|issue=5754|pages=316–320|doi=10.1038/284316a0|issn=1476-4687|via=}}</ref> in the laboratory of [[Charles Weissmann]] at the [[University of Zurich]].<ref>{{Citation|last=Weissmann|first=Charles|title=Recombinant interferon - the 20th anniversary|date=2001|url=https://doi.org/10.1007/978-3-0348-8346-7_1|work=Recombinant Protein Drugs|pages=3–41|editor-last=Buckel|editor-first=Peter|series=Milestones in Drug Therapy|publisher=Birkhäuser|language=en|doi=10.1007/978-3-0348-8346-7_1|isbn=978-3-0348-8346-7|access-date=2020-03-20}}</ref><ref>{{Cite journal|last=Mantei|first=Ned|last2=Schwarzstein|first2=Marco|last3=Streuli|first3=Michel|last4=Panem|first4=Sandra|last5=Nagata|first5=Shigekazu|last6=Weissmann|first6=Charles|date=1980-06-01|title=The nucleotide sequence of a cloned human leukocyte Interferon cDNA|url=http://www.sciencedirect.com/science/article/pii/0378111980901377|journal=Gene|language=en|volume=10|issue=1|pages=1–10|doi=10.1016/0378-1119(80)90137-7|issn=0378-1119}}</ref> It was developed at [[Biogen]], and ultimately marketed by Schering-Plough under the trade name '''Intron-A'''. It has been used for a wide range of indications, including viral infections and cancers.
'''Interferon alfa-2b''' is an antiviral or [[antineoplastic]] drug. It is a [[recombinant DNA|recombinant]] form of the protein [[IFNA2|Interferon alpha-2]] that was originally sequenced and produced recombinantly in ''[[E. coli]]''<ref>{{cite journal | vauthors = Nagata S, Taira H, Hall A, Johnsrud L, Streuli M, Ecsödi J, Boll W, Cantell K, Weissmann C | display-authors = 6 | title = Synthesis in E. coli of a polypeptide with human leukocyte interferon activity | journal = Nature | volume = 284 | issue = 5754 | pages = 316–320 | date = March 1980 | pmid = 6987533 | doi = 10.1038/284316a0 | s2cid = 4310807 | bibcode = 1980Natur.284..316N }}</ref> in the laboratory of [[Charles Weissmann]] at the [[University of Zurich]], in 1980.<ref>{{cite book| vauthors = Weissmann C |chapter=Recombinant interferon - the 20th anniversary|date=2001|title=Recombinant Protein Drugs|pages=3–41| veditors = Buckel P |series=Milestones in Drug Therapy|publisher=Birkhäuser|location=Basel|doi=10.1007/978-3-0348-8346-7_1|isbn=978-3-0348-8346-7}}</ref><ref>{{cite journal | vauthors = Mantei N, Schwarzstein M, Streuli M, Panem S, Nagata S, Weissmann C | title = The nucleotide sequence of a cloned human leukocyte interferon cDNA | journal = Gene | volume = 10 | issue = 1 | pages = 1–10 | date = June 1980 | pmid = 6157600 | doi = 10.1016/0378-1119(80)90137-7 }}</ref> It was developed at [[Biogen]], and ultimately marketed by Schering-Plough under the trade name '''Intron-A'''. It was also produced in 1986 in recombinant human form, in the [[Center for Genetic Engineering and Biotechnology]] of Havana, Cuba, under the name Heberon Alfa R.<ref>{{Cite journal| vauthors = Nodarse-Cuní H, López-Saura PA |date=2017|title=Cuban interferon alpha-2b. Thirty years as an effective and safe drug|url=https://www.medigraphic.com/cgi-bin/new/resumenI.cgi?IDARTICULO=75882|journal=Biotecnología Aplicada|volume=34|issue=1|pages=1211–1217|issn=1027-2852}}</ref>


This drug is approved around the world for the treatment of chronic [[hepatitis C]], chronic [[hepatitis B]], [[hairy cell leukemia]], [[Behçet's disease]], chronic [[myelogenous leukemia]], multiple myeloma, [[follicular lymphoma]], carcinoid tumor, [[mastocytosis]] and malignant melanoma.
It has been used for a wide range of indications, including viral infections and cancers. This drug is approved around the world for the treatment of chronic [[hepatitis C]], chronic [[hepatitis B]], [[hairy cell leukemia]], [[Behçet's disease]], chronic [[myelogenous leukemia]], multiple myeloma, [[follicular lymphoma]], carcinoid tumor, [[mastocytosis]] and malignant melanoma.{{Citation needed|reason=Reliable source needed for the whole sentence|date=March 2020}}


The medication has also been used in clinical trials to treat patients with [[SARS-CoV-2]].<ref name="auto">{{Cite web|url=https://www.newsweek.com/cuba-drug-fight-coronavirus-us-sanctions-1493872|title=Cuba uses "wonder drug" to fight coronavirus around the world despite U.S. sanctions|first=Tom O'Connor On 3/24/20 at 5:34 PM|last=EDT|date=March 24, 2020|website=Newsweek}}</ref>
The medication is being used in clinical trials to treat patients with [[SARS-CoV-2]]<ref name="auto">{{Cite web|url=https://www.newsweek.com/cuba-drug-fight-coronavirus-us-sanctions-1493872|title=Cuba uses "wonder drug" to fight coronavirus around the world despite U.S. sanctions| vauthors = O'Connor T |date=March 24, 2020|website=Newsweek}}</ref> and there are published results in the peer-reviewed scientific literature.<ref name=ivermectin>{{cite journal | vauthors = Pereda R, González D, Rivero HB, Rivero JC, Pérez A, Lopez LD, Mezquia N, Venegas R, Betancourt JR, Domínguez RE, Nodarse H | display-authors = 6 | title = Therapeutic Effectiveness of Interferon Alpha 2b Treatment for COVID-19 Patient Recovery | journal = Journal of Interferon & Cytokine Research | volume = 40 | issue = 12 | pages = 578–588 | date = December 2020 | pmid = 33337933 | doi = 10.1089/jir.2020.0188 | s2cid = 229324680 }}</ref>


So far, two non-peer reviewed research articles have been published. One study at the [[University of Texas Medical Branch]], Galveston, showed evidence of a direct anti-viral effect of Interferon alpha against novel Coronavirus in vitro. The study demonstrated around 10,000 fold reduction in the quantity of virus that was pre-treated with Interferon alpha 48 hours earlier. A second study by universities in China, Australia and Canada analysed 77 moderate COVID-19 subjects in Wuhan and observed that those who received Interferon alpha-2b showed a significant reduction in the duration of virus shedding period and even in levels of the inflammatory cytokine, IL-6. <ref>{{Cite news|url=https://timesofindia.indiatimes.com/business/india-business/zydus-to-test-use-of-hep-c-med-for-virus/articleshow/75260635.cms|title = Zydus to test use of Hepatitis C medicine for virus | website=[[The Times of India]] | date=21 April 2020 }}</ref> <ref>{{Cite news|url=https://www.reuters.com/article/brief-zydus-explores-biologicals-route-t-idUSFWN2C51DU|title = BRIEF-Zydus Explores Biologicals Route to Treat Coronavirus with Interferon Alpha-2B|newspaper = Reuters|date = 20 April 2020}}</ref>
{| class="Wikitable"|style="margin: 1em auto 1em auto" border="1"

⚫
!colspan="4"|Interferon alfa-2b products<ref>{{cite journal|url=http://www.pharma2020.ru/spaw2/uploads/files/321.pdf?pharma2020=091cae460ddce3b1fbe0d97fdf63e4ae|title=Russia through the prism of the world biopharmaceutical market|author=Dmitrij I. Bairamashvili1 and Mikhail L. Rabinovich2*|year=2007|journal=Biotechnol. J.|volume=2|access-date=2009-06-14|archive-url=https://web.archive.org/web/20120224134036/http://www.pharma2020.ru/spaw2/uploads/files/321.pdf?pharma2020=091cae460ddce3b1fbe0d97fdf63e4ae|archive-date=2012-02-24|url-status=dead}}</ref>
This drug is also used off-label in cats and dogs, both by injection and orally.<ref name="WW">{{cite web | vauthors = Forney B |date= |title=Interferon Alpha-2B for Veterinary Use |url=https://www.wedgewoodpharmacy.com/learning-center/professional-monographs/interferon-alpha-2b-for-veterinary-use.html |archive-url=https://web.archive.org/web/20211019032534/https://www.wedgewoodpharmacy.com/learning-center/professional-monographs/interferon-alpha-2b-for-veterinary-use.html |archive-date=2021-10-19 |website=Wedgewood Pharmacy}}</ref> The cross-species nature of IFN-α allow it to work in non-human animals,<ref name=Yang07>{{cite journal | vauthors = Yang LM, Xue QH, Sun L, Zhu YP, Liu WJ | title = Cloning and characterization of a novel feline IFN-omega | journal = Journal of Interferon & Cytokine Research | volume = 27 | issue = 2 | pages = 119–127 | date = February 2007 | pmid = 17316139 | doi = 10.1089/jir.2006.0094 }}</ref> but the period of usefulness is limited by the production of antibodies against this foreign protein.<ref name=WW/>

{| class="wikitable"
⚫
!colspan="4"|Interferon alfa-2b products<ref>{{cite journal|url=http://www.pharma2020.ru/spaw2/uploads/files/321.pdf?pharma2020=091cae460ddce3b1fbe0d97fdf63e4ae|title=Russia through the prism of the world biopharmaceutical market| vauthors = Bairamashvili DI, Rabinovich ML |year=2007|journal=Biotechnol. J.|volume=2|issue=7 |pages=801–817 |doi=10.1002/biot.200700091 |pmid=17615600 |s2cid=26770545 |access-date=2009-06-14|archive-url=https://web.archive.org/web/20120224134036/http://www.pharma2020.ru/spaw2/uploads/files/321.pdf?pharma2020=091cae460ddce3b1fbe0d97fdf63e4ae|archive-date=2012-02-24|url-status=dead}}</ref>
|-
|-
!Product
!Product
Line 95: Line 100:
| Kipferon
| Kipferon
|[[Alfarm]]
|[[Alfarm]]
| combination with [[IgM]], [[IgA]], [[IgG]]
| combination with [[IgM]], [[IgA]], [[Immunoglobulin G|IgG]]
|
|
|-
|-
Line 112: Line 117:
| with [[dimedrol]]
| with [[dimedrol]]
| eye infections
| eye infections
|-
| Heberon Alfa R
|[[BioCubaFarma]], Cuban-Chinese joint venture [[ChangHeber]]<ref>{{Cite web | vauthors = Makichuk D |url=https://asiatimes.com/2020/04/covid-contenders-viral-drugs-that-offer-hope/|title=Covid contenders: Viral drugs that offer hope | work = Asia Times |date=18 April 2020}}</ref><ref>{{Cite web|url=https://oncubanews.com/en/cuba/the-famous-cuban-interferon-vs-the-sars-cov-2-coronavirus/|title = The famous Cuban interferon vs the SARS-CoV-2 coronavirus|date = 19 March 2020}}</ref>
|
| [[severe acute respiratory syndrome (SARS)]], [[Middle East respiratory syndrome]] (MERS), [[SARS-CoV-2|Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)]]<ref>{{Cite web|url=https://amerika21.de/2020/03/238594/interferon-kuba-deutschland|title=Medikament aus Kuba zur Behandlung des Coronavirus bald auch in Deutschland?|date=30 March 2020}}</ref>
|-
|-
|}
|}


==See also==
== See also ==
* [[Interferon]]
* [[Interferon]]
* [[Ropeginterferon alfa-2b]]


==References==
== References ==
{{Reflist}}
<references />


== Further reading ==
⚫
==External links==
{{Commonscat}}
{{refbegin}}
*[https://web.archive.org/web/20091107054423/http://www.emea.europa.eu/humandocs/PDFs/EPAR/Introna/H-281-PI-en.pdf Intron-A Summary of Product Characteristics]
* {{cite web | url = http://www.emea.europa.eu/humandocs/PDFs/EPAR/Introna/H-281-PI-en.pdf | title = Intron-A Summary of Product Characteristics | publisher = European Medicines Agency | archive-url = https://web.archive.org/web/20091107054423/http://www.emea.europa.eu/humandocs/PDFs/EPAR/Introna/H-281-PI-en.pdf | archive-date = 2009-11-07 }}
*{{cite journal |vauthors=Nagata S, Taira H, Hall A, etal |title=Synthesis in E. coli of a polypeptide with human leukocyte interferon activity |journal=[[Nature (journal)|Nature]] |volume=284 |issue=5754 |pages=316–20 |date=Mar 1980 |pmid=6987533 |doi=10.1038/284316a0 }}
* {{cite journal | vauthors = Nagata S, Taira H, Hall A, Johnsrud L, Streuli M, Ecsödi J, Boll W, Cantell K, Weissmann C | display-authors = 6 | title = Synthesis in E. coli of a polypeptide with human leukocyte interferon activity | journal = Nature | volume = 284 | issue = 5754 | pages = 316–320 | date = March 1980 | pmid = 6987533 | doi = 10.1038/284316a0 | s2cid = 4310807 | bibcode = 1980Natur.284..316N }}
{{refend}}

⚫
== External links ==
{{Commons category}}


{{Interferons}}
{{Interferons}}
Line 132: Line 147:
{{Cytokine receptor modulators}}
{{Cytokine receptor modulators}}


[[Category:Antivirals]]
[[Category:Antiviral drugs]]
⚫
[[Category:Drugs developed by Schering-Plough]]
⚫
[[Category:Drugs developed by Merck & Co.]]

{{antiinfective-drug-stub}}
{{antiinfective-drug-stub}}
{{antineoplastic-drug-stub}}
{{antineoplastic-drug-stub}}
⚫
[[Category:Schering-Plough brands]]
⚫
[[Category:Merck & Co. brands]]

Latest revision as of 08:11, 15 September 2024

Interferon alfa-2b
Clinical data
MedlinePlusa690006
License data
Routes of
administration		Subcutaneous, intramuscular
ATC code
Legal status
Legal status
Identifiers
CAS Number
IUPHAR/BPS
DrugBank
ChemSpider
  • none
UNII
ChEMBL
ECHA InfoCard100.208.165 Edit this at Wikidata
 ☒NcheckY (what is this?)  (verify)

Interferon alfa-2b is an antiviral or antineoplastic drug. It is a recombinant form of the protein Interferon alpha-2 that was originally sequenced and produced recombinantly in E. coli[1] in the laboratory of Charles Weissmann at the University of Zurich, in 1980.[2][3] It was developed at Biogen, and ultimately marketed by Schering-Plough under the trade name Intron-A. It was also produced in 1986 in recombinant human form, in the Center for Genetic Engineering and Biotechnology of Havana, Cuba, under the name Heberon Alfa R.[4]

It has been used for a wide range of indications, including viral infections and cancers. This drug is approved around the world for the treatment of chronic hepatitis C, chronic hepatitis B, hairy cell leukemia, Behçet's disease, chronic myelogenous leukemia, multiple myeloma, follicular lymphoma, carcinoid tumor, mastocytosis and malignant melanoma.[citation needed]

The medication is being used in clinical trials to treat patients with SARS-CoV-2[5] and there are published results in the peer-reviewed scientific literature.[6]

So far, two non-peer reviewed research articles have been published. One study at the University of Texas Medical Branch, Galveston, showed evidence of a direct anti-viral effect of Interferon alpha against novel Coronavirus in vitro. The study demonstrated around 10,000 fold reduction in the quantity of virus that was pre-treated with Interferon alpha 48 hours earlier. A second study by universities in China, Australia and Canada analysed 77 moderate COVID-19 subjects in Wuhan and observed that those who received Interferon alpha-2b showed a significant reduction in the duration of virus shedding period and even in levels of the inflammatory cytokine, IL-6. [7] [8]

This drug is also used off-label in cats and dogs, both by injection and orally.[9] The cross-species nature of IFN-α allow it to work in non-human animals,[10] but the period of usefulness is limited by the production of antibodies against this foreign protein.[9]

Interferon alfa-2b products[11]
Product Manufacturer Features Special uses
Alpharona Pharmaclon
Intron-A/IntronA Schering-Plough
Realderon Teva
Reaferon EC GNC Vector
Reaferon EC-Lipint Vector-Medica liposomal
Infagel Vector-Medica ointment
Recolin Vector-Medica
Altevir Bioprocess subsidiary liquid, free of HSA
Kipferon Alfarm combination with IgM, IgA, IgG
Giaferon A/S Vitafarma
Genferon Biocad
Opthalamoferon Firn-M with dimedrol eye infections
Heberon Alfa R BioCubaFarma, Cuban-Chinese joint venture ChangHeber[12][13] severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)[14]

See also

[edit]

References

[edit]
  1. ^ Nagata S, Taira H, Hall A, Johnsrud L, Streuli M, Ecsödi J, et al. (March 1980). "Synthesis in E. coli of a polypeptide with human leukocyte interferon activity". Nature. 284 (5754): 316–320. Bibcode:1980Natur.284..316N. doi:10.1038/284316a0. PMID 6987533. S2CID 4310807.
  2. ^ Weissmann C (2001). "Recombinant interferon - the 20th anniversary". In Buckel P (ed.). Recombinant Protein Drugs. Milestones in Drug Therapy. Basel: Birkhäuser. pp. 3–41. doi:10.1007/978-3-0348-8346-7_1. ISBN 978-3-0348-8346-7.
  3. ^ Mantei N, Schwarzstein M, Streuli M, Panem S, Nagata S, Weissmann C (June 1980). "The nucleotide sequence of a cloned human leukocyte interferon cDNA". Gene. 10 (1): 1–10. doi:10.1016/0378-1119(80)90137-7. PMID 6157600.
  4. ^ Nodarse-Cuní H, López-Saura PA (2017). "Cuban interferon alpha-2b. Thirty years as an effective and safe drug". Biotecnología Aplicada. 34 (1): 1211–1217. ISSN 1027-2852.
  5. ^ O'Connor T (March 24, 2020). "Cuba uses "wonder drug" to fight coronavirus around the world despite U.S. sanctions". Newsweek.
  6. ^ Pereda R, González D, Rivero HB, Rivero JC, Pérez A, Lopez LD, et al. (December 2020). "Therapeutic Effectiveness of Interferon Alpha 2b Treatment for COVID-19 Patient Recovery". Journal of Interferon & Cytokine Research. 40 (12): 578–588. doi:10.1089/jir.2020.0188. PMID 33337933. S2CID 229324680.
  7. ^ "Zydus to test use of Hepatitis C medicine for virus". The Times of India. 21 April 2020.
  8. ^ "BRIEF-Zydus Explores Biologicals Route to Treat Coronavirus with Interferon Alpha-2B". Reuters. 20 April 2020.
  9. ^ a b Forney B. "Interferon Alpha-2B for Veterinary Use". Wedgewood Pharmacy. Archived from the original on 2021-10-19.
  10. ^ Yang LM, Xue QH, Sun L, Zhu YP, Liu WJ (February 2007). "Cloning and characterization of a novel feline IFN-omega". Journal of Interferon & Cytokine Research. 27 (2): 119–127. doi:10.1089/jir.2006.0094. PMID 17316139.
  11. ^ Bairamashvili DI, Rabinovich ML (2007). "Russia through the prism of the world biopharmaceutical market" (PDF). Biotechnol. J. 2 (7): 801–817. doi:10.1002/biot.200700091. PMID 17615600. S2CID 26770545. Archived from the original (PDF) on 2012-02-24. Retrieved 2009-06-14.
  12. ^ Makichuk D (18 April 2020). "Covid contenders: Viral drugs that offer hope". Asia Times.
  13. ^ "The famous Cuban interferon vs the SARS-CoV-2 coronavirus". 19 March 2020.
  14. ^ "Medikament aus Kuba zur Behandlung des Coronavirus bald auch in Deutschland?". 30 March 2020.

Further reading

[edit]
[edit]
Wikimedia Commons has media related to Interferon alfa-2b.
Stub icon

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Interferon_alfa-2b&oldid=1245813717"